PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21283018-1	2011	OBJECTIVE: Recently, we reported that pranlukast, an antagonist of cysteinyl leukotriene receptor 1, attenuates ischemic injury in endothelial cells by decreasing reactive oxygen species (ROS) production and inhibiting nuclear factor-kappaB activation in a leukotriene-independent manner.	pranlukast	38-48	cysteinyl leukotriene receptor 1	Homo sapiens	67-99
21482134-6	2011	We also determined the inhibitory effects of pranlukast, a CysLT(1) receptor antagonist, on VEGF production by LTD(4) stimulation.	pranlukast	45-55	vascular endothelial growth factor A	Homo sapiens	92-96
21482134-9	2011	In addition, 10(-7)-10(-10)M pranlukast completely inhibited VEGF production enhanced by LTD(4).	pranlukast	29-39	vascular endothelial growth factor A	Homo sapiens	61-65
21799837-11	2011	Pranlukast inhibited the UDP-evoked I(SC) potentiated by an Epac activator, 8-(4-Chlorophenylthio)-2"-O-methyladenosine-3",5"-cyclic monophosphate (8-CPT-2"-O-Me-cAMP), while montelukast and zafirlukast had no such effect.	pranlukast	0-10	Rap guanine nucleotide exchange factor 3	Homo sapiens	60-64
18802359-6	2009	Pranlukast blocked MIP-1alpha and MIP-1beta production promoted by LTD(4) in THP-1 cells and PBMCs.	pranlukast	0-10	C-C motif chemokine ligand 3	Homo sapiens	19-29
20560805-0	2010	Serum interleukin-5 levels correlate with disease activity of Churg-Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid.	pranlukast	146-156	interleukin 5	Homo sapiens	6-19
20233425-3	2010	Here, we applied docking and molecular dynamics simulations (MD) to analyse the binding and the forced unbinding of two GPR17 ligands (the endogenous purinergic agonist UDP and the leukotriene receptor antagonist pranlukast from both the wild-type (WT) receptor and a mutant model, where a basic residue hypothesized to be crucial for nucleotide binding had been mutated (R255I) to Ile.	pranlukast	213-223	G protein-coupled receptor 17	Homo sapiens	120-125
20433311-6	2010	We also investigated whether the CysLT1 receptor antagonist pranlukast inhibits CysLT-induced RANTES release.	pranlukast	60-70	C-C motif chemokine ligand 5	Homo sapiens	94-100
19336906-4	2009	On the other hand, pranlukast reversibly inhibited CYP2C8 and/or 2C9, and CYP3A4, with K(i) values of 3.9 and 4.1 micromol/l, respectively.	pranlukast	19-29	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	51-57
19336906-4	2009	On the other hand, pranlukast reversibly inhibited CYP2C8 and/or 2C9, and CYP3A4, with K(i) values of 3.9 and 4.1 micromol/l, respectively.	pranlukast	19-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
19703064-2	2009	We have reported that genetic variability in the expression of LTC(4) synthase is associated with responsiveness to pranlukast in Japanese asthmatic patients.	pranlukast	116-126	leukotriene C4 synthase	Homo sapiens	63-78
19703064-9	2009	Univariate and multivariate analyses showed that LTC(4) synthase polymorphisms, but not the CL/F of the drug, predicted an improvement in pulmonary function with pranlukast treatment (P < 0.05).	pranlukast	162-172	leukotriene C4 synthase	Homo sapiens	49-64
18802359-6	2009	Pranlukast blocked MIP-1alpha and MIP-1beta production promoted by LTD(4) in THP-1 cells and PBMCs.	pranlukast	0-10	C-C motif chemokine ligand 4	Homo sapiens	34-43
19218821-9	2009	Pranlukast inhibited phosphorylation of ERK1/2 and JNK, NF-kappaB activation, and the MCP-1 production induced by CysLTs.	pranlukast	0-10	mitogen-activated protein kinase 3	Homo sapiens	40-46
19129732-0	2009	Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-kappaB activation.	pranlukast	0-10	nuclear factor kappa B subunit 1	Homo sapiens	118-139
19218821-9	2009	Pranlukast inhibited phosphorylation of ERK1/2 and JNK, NF-kappaB activation, and the MCP-1 production induced by CysLTs.	pranlukast	0-10	mitogen-activated protein kinase 8	Homo sapiens	51-54
19218821-9	2009	Pranlukast inhibited phosphorylation of ERK1/2 and JNK, NF-kappaB activation, and the MCP-1 production induced by CysLTs.	pranlukast	0-10	nuclear factor kappa B subunit 1	Homo sapiens	56-65
19218821-9	2009	Pranlukast inhibited phosphorylation of ERK1/2 and JNK, NF-kappaB activation, and the MCP-1 production induced by CysLTs.	pranlukast	0-10	C-C motif chemokine ligand 2	Homo sapiens	86-91
18176092-7	2008	Pranlukast, which is a selective antagonist of CysLT(1) receptor, inhibited LTD(4)-induced MUC2 gene transcriptional activity in a dose-dependent manner.	pranlukast	0-10	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	91-95
19129732-1	2009	The anti-inflammatory effects of pranlukast, an antagonist of cysteinyl leukotriene receptor 1, may be rendered not only by antileukotriene activity but also by other pharmacological activities.	pranlukast	33-43	cysteinyl leukotriene receptor 1	Homo sapiens	62-94
19129732-13	2009	Thus, we conclude that pranlukast protects endothelial cells from ischemia-like injury via decreasing ROS production and inhibiting NF-kappaB activation, which is leukotriene independent.	pranlukast	23-33	nuclear factor kappa B subunit 1	Homo sapiens	132-141
18176092-9	2008	In addition, pranlukast inhibited LTD(4)-induced NF-kappaB activity.	pranlukast	13-23	nuclear factor kappa B subunit 1	Homo sapiens	49-58
18689991-6	2008	RESULTS: Adding pranlukast did not further improve blood eosinophil counts, pulmonary function and symptoms, but significantly attenuated sputum cysteinyl leukotrienes, tumor necrosis factor-alpha and interleukin-5 concentrations.	pranlukast	16-26	tumor necrosis factor	Homo sapiens	169-196
18689991-6	2008	RESULTS: Adding pranlukast did not further improve blood eosinophil counts, pulmonary function and symptoms, but significantly attenuated sputum cysteinyl leukotrienes, tumor necrosis factor-alpha and interleukin-5 concentrations.	pranlukast	16-26	interleukin 5	Homo sapiens	201-214
17706964-9	2007	Anaphylaxis-induced increase in Rpre was most extensively inhibited by 38.6% by pretreatment with ONO-1078 (100 microM, a cysteinyl leukotriene receptor-1 antagonist), among all antagonists or inhibitors administrated individually including TCV-309 (20 microM), AA-2414 (10 microM), ketanserin (10 microM) and indomethacin (10 microM).	pranlukast	98-106	cysteinyl leukotriene receptor 1	Rattus norvegicus	122-154
19122337-2	2008	In vitro data suggest that pranlukast is a substrate of CYP3A4.	pranlukast	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
17223000-8	2007	Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion.	pranlukast	20-28	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	85-89
18236018-0	2007	Protective effect of pranlukast, a cysteinyl-leukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats.	pranlukast	21-31	cysteinyl leukotriene receptor 1	Rattus norvegicus	35-67
17223000-8	2007	Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion.	pranlukast	20-28	LOC100508689	Homo sapiens	114-119
17223000-5	2007	METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	pranlukast	101-109	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	132-136
17010308-6	2006	The selective CysLT(1) receptor antagonist pranlukast inhibited the IgG exudation, but not the increased water content and AQP4 expression induced by LTD(4).	pranlukast	43-53	cysteinyl leukotriene receptor 1	Rattus norvegicus	14-22
17430359-5	2007	In addition, we examined the effect of pranlukast, a cysLT1 receptor antagonist, on the enhancement of TNF-alpha-induced MMP-9 production by cysLTs.	pranlukast	39-49	tumor necrosis factor	Homo sapiens	103-112
17430359-5	2007	In addition, we examined the effect of pranlukast, a cysLT1 receptor antagonist, on the enhancement of TNF-alpha-induced MMP-9 production by cysLTs.	pranlukast	39-49	matrix metallopeptidase 9	Homo sapiens	121-126
17430359-8	2007	Moreover, we demonstrated that pranlukast completely inhibited the enhancement of TNF-alpha-induced MMP-9 production by LTC4 and -D4 in THP-1 cells and peripheral blood CD14+ monocytes/macrophages.	pranlukast	31-41	tumor necrosis factor	Homo sapiens	82-91
17430359-8	2007	Moreover, we demonstrated that pranlukast completely inhibited the enhancement of TNF-alpha-induced MMP-9 production by LTC4 and -D4 in THP-1 cells and peripheral blood CD14+ monocytes/macrophages.	pranlukast	31-41	matrix metallopeptidase 9	Homo sapiens	100-105
17430359-8	2007	Moreover, we demonstrated that pranlukast completely inhibited the enhancement of TNF-alpha-induced MMP-9 production by LTC4 and -D4 in THP-1 cells and peripheral blood CD14+ monocytes/macrophages.	pranlukast	31-41	CD14 molecule	Homo sapiens	169-173
17588329-6	2007	CONCLUSION: The CysLT1 receptor modulates cryoinjury in mice at least partly, and postinjury treatment with its antagonist pranlukast exerts the protective effect with a therapeutic window of 30 min.	pranlukast	123-133	cysteinyl leukotriene receptor 1	Mus musculus	16-22
17443897-0	2007	[Cysteinyl leukotriene receptor 1 antagonist pranlukast modulates differentiation of SK-N-SH cells].	pranlukast	45-55	cysteinyl leukotriene receptor 1	Homo sapiens	1-33
17443897-6	2007	The immunostaining results showed that MAP-2 was distributed in the cell bodies in control or pranlukast-treated cells; it was distributed in cell bodies and neuritis in RA-treated cells.	pranlukast	94-104	microtubule associated protein 2	Homo sapiens	39-44
17443897-7	2007	Pranlukast increased the numbers of MAP-2-positive cells.	pranlukast	0-10	microtubule associated protein 2	Homo sapiens	36-41
17132213-9	2006	Although pranlukast is devoid of anionic motifs other than the tetrazole group, it potently inhibited the OAT4-mediated uptake of estrone-3-sulfate, indicating that a tetrazole group may be one important structural feature in substrate recognition by OAT4.	pranlukast	9-19	solute carrier family 22 member 11	Homo sapiens	106-110
17132213-9	2006	Although pranlukast is devoid of anionic motifs other than the tetrazole group, it potently inhibited the OAT4-mediated uptake of estrone-3-sulfate, indicating that a tetrazole group may be one important structural feature in substrate recognition by OAT4.	pranlukast	9-19	solute carrier family 22 member 11	Homo sapiens	251-255
16892782-13	2006	In contrast, pranlukast specifically inhibited IL-5 but not IFN-gamma.	pranlukast	13-23	interleukin 5	Homo sapiens	47-51
17112405-5	2006	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Mus musculus	146-152
17112405-5	2006	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor.	pranlukast	66-76	cysteinyl leukotriene receptor 1	Mus musculus	146-152
16864492-1	2006	CONCLUSION: The high density of [3H]-pranlukast binding sites on the local leukocytes in human nasal mucosa suggests that CysLT1 receptor antagonists may directly modulate cellular function of the local leukocytes through binding to CysLT1 receptor on allergic nasal mucosa.	pranlukast	37-47	cysteinyl leukotriene receptor 1	Homo sapiens	122-128
16864492-1	2006	CONCLUSION: The high density of [3H]-pranlukast binding sites on the local leukocytes in human nasal mucosa suggests that CysLT1 receptor antagonists may directly modulate cellular function of the local leukocytes through binding to CysLT1 receptor on allergic nasal mucosa.	pranlukast	37-47	cysteinyl leukotriene receptor 1	Homo sapiens	233-239
16973153-0	2006	Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Mus musculus	14-46
16973153-2	2006	Here, we further determined the protective effect of pranlukast, a CysLT1 receptor antagonist, on brain cold injury in mice.	pranlukast	53-63	cysteinyl leukotriene receptor 1	Mus musculus	67-73
16808814-6	2006	Additionally, pranlukast-induced fibronectin protein production by human mesenchymal stem cells.	pranlukast	14-24	fibronectin 1	Homo sapiens	33-44
15609771-7	2004	Pranlukast, a cysLT1 receptor antagonist, significantly inhibited all of these parameters, although the inhibitory effect on O2- generation was partial.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Homo sapiens	14-20
16490162-1	2006	AIM: To determine whether pranlukast, a cysteinyl leukotriene receptor-1 antagonist, exerts an anti-inflammatory effect on focal cerebral ischemia in mice.	pranlukast	26-36	cysteinyl leukotriene receptor 1	Mus musculus	40-72
16490162-6	2006	Importantly, pranlukast (0.01 and 0.1 mg/kg) inhibited myeloperoxidase-positive neutrophil, but not CD11b-positive macrophage/microglial accumulation in the ischemic cortical tissue.	pranlukast	13-23	myeloperoxidase	Mus musculus	55-70
16280122-1	2005	Montelukast and pranlukast are orally active leukotriene receptor antagonists selective for the CysLT1 receptor.	pranlukast	16-26	cysteinyl leukotriene receptor 1	Homo sapiens	96-102
16008674-6	2005	RESULTS: Pranlukast reduced IL-10 and increased IL-12, while fluticasone reduced both IL-10 and IL-12 production by mite allergen-pulsed DCs.	pranlukast	9-19	interleukin 10	Mus musculus	28-33
15650315-0	2005	Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.	pranlukast	0-10	interleukin 5	Homo sapiens	56-69
15650315-1	2005	BACKGROUND: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.	pranlukast	12-22	cysteinyl leukotriene receptor 1	Homo sapiens	26-58
15650315-1	2005	BACKGROUND: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.	pranlukast	12-22	cysteinyl leukotriene receptor 1	Homo sapiens	60-67
15650315-2	2005	The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation.	pranlukast	56-66	interleukin 5	Homo sapiens	75-88
15650315-2	2005	The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation.	pranlukast	56-66	interleukin 5	Homo sapiens	90-94
15650315-5	2005	RESULTS: Pretreatment of lung tissues with pranlukast alone significantly decreased the amount of IL-5 protein in the culture medium by 40%.	pranlukast	43-53	interleukin 5	Homo sapiens	98-102
15650315-9	2005	Pranlukast-induced inhibition of IL-5 mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.	pranlukast	0-10	interleukin 5	Homo sapiens	33-37
15650315-11	2005	CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism.	pranlukast	38-48	interleukin 5	Homo sapiens	58-62
15475658-0	2005	Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells.	pranlukast	0-10	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	45-49
15475658-9	2005	Pranlukast also significantly inhibited LPS-induced MUC2 mRNA expression by reverse transcription-polymerase chain reaction (RT-PCR) analysis in NCI-H292 cells.	pranlukast	0-10	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	52-56
15475658-10	2005	Pranlukast also inhibited LPS-induced MUC2 gene expression in HM3-MUC2 cells.	pranlukast	0-10	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	38-42
15475658-10	2005	Pranlukast also inhibited LPS-induced MUC2 gene expression in HM3-MUC2 cells.	pranlukast	0-10	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	66-70
15475658-12	2005	These results suggest that pranlukast may inhibit NF-kappaB activation and MUC2 gene transcription through pathways distinct from cysLT(1) receptor antagonism in cultured human epithelial cells.	pranlukast	27-37	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	75-79
15452361-1	2005	Our previous studies showed that cysteinyl leukotriene receptor-1 (CysLT1) antagonist pranlukast has a neuroprotective effect on cerebral ischemia in rats and mice.	pranlukast	86-96	cysteinyl leukotriene receptor 1	Rattus norvegicus	33-65
15452361-1	2005	Our previous studies showed that cysteinyl leukotriene receptor-1 (CysLT1) antagonist pranlukast has a neuroprotective effect on cerebral ischemia in rats and mice.	pranlukast	86-96	cysteinyl leukotriene receptor 1	Rattus norvegicus	67-73
16369813-0	2006	Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers.	pranlukast	60-64	peptidylprolyl isomerase G	Homo sapiens	130-133
16164450-7	2005	Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, blocked MCP-1 production by CysLTs in THP-1 cells almost completely, and partially inhibited MCP-1 release by CysLTs in peripheral blood CD14+ monocytes/macrophages and CCR2B expression by CysLTs in THP-1 cells.	pranlukast	31-41	cysteinyl leukotriene receptor 1	Mus musculus	45-51
16164450-7	2005	Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, blocked MCP-1 production by CysLTs in THP-1 cells almost completely, and partially inhibited MCP-1 release by CysLTs in peripheral blood CD14+ monocytes/macrophages and CCR2B expression by CysLTs in THP-1 cells.	pranlukast	31-41	chemokine (C-C motif) ligand 2	Mus musculus	81-86
16164450-7	2005	Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, blocked MCP-1 production by CysLTs in THP-1 cells almost completely, and partially inhibited MCP-1 release by CysLTs in peripheral blood CD14+ monocytes/macrophages and CCR2B expression by CysLTs in THP-1 cells.	pranlukast	31-41	C-C motif chemokine ligand 2	Homo sapiens	166-171
16164450-7	2005	Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, blocked MCP-1 production by CysLTs in THP-1 cells almost completely, and partially inhibited MCP-1 release by CysLTs in peripheral blood CD14+ monocytes/macrophages and CCR2B expression by CysLTs in THP-1 cells.	pranlukast	31-41	CD14 molecule	Homo sapiens	210-214
16164450-7	2005	Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, blocked MCP-1 production by CysLTs in THP-1 cells almost completely, and partially inhibited MCP-1 release by CysLTs in peripheral blood CD14+ monocytes/macrophages and CCR2B expression by CysLTs in THP-1 cells.	pranlukast	31-41	C-C motif chemokine receptor 2	Homo sapiens	242-247
16051204-0	2005	Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Mus musculus	14-46
16051204-1	2005	We have recently reported the neuroprotective effect of pranlukast (ONO-1078), a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, on cerebral ischemia in rats and mice.	pranlukast	56-66	cysteinyl leukotriene receptor 1	Rattus norvegicus	81-113
16051204-1	2005	We have recently reported the neuroprotective effect of pranlukast (ONO-1078), a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, on cerebral ischemia in rats and mice.	pranlukast	56-66	cysteinyl leukotriene receptor 1	Rattus norvegicus	115-121
16051204-1	2005	We have recently reported the neuroprotective effect of pranlukast (ONO-1078), a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, on cerebral ischemia in rats and mice.	pranlukast	68-76	cysteinyl leukotriene receptor 1	Rattus norvegicus	81-113
16051204-1	2005	We have recently reported the neuroprotective effect of pranlukast (ONO-1078), a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, on cerebral ischemia in rats and mice.	pranlukast	68-76	cysteinyl leukotriene receptor 1	Rattus norvegicus	115-121
16051204-8	2005	At the end of the experiment, pranlukast significantly reduced lesion volume, and increased neuron densities in the cortex and hippocampal CA1 region in the ischemic hemispheres.	pranlukast	30-40	carbonic anhydrase 1	Mus musculus	139-142
15780192-0	2005	ONO-1078 reduces NMDA-induced brain injury and vascular cell adhesion molecule-1 expression in rats.	pranlukast	0-8	vascular cell adhesion molecule 1	Rattus norvegicus	47-80
15780192-1	2005	AIM: To determine whether ONO-1078 (pranlukast), a potent cysteinyl leukotriene receptor 1 (CysLT1) antagonist, has an effect on N-methyl-D-aspartate (NMDA)-induced brain injury and vascular cell adhesion molecule-1 (VCAM-1) expression in rats.	pranlukast	26-34	cysteinyl leukotriene receptor 1	Rattus norvegicus	58-90
15780192-7	2005	Furthermore, ONO-1078 (0.1, 0.3 mg/kg) significantly inhibited the enhanced expression of VCAM-1 in the injured cortices, but edaravone did not have this effect.	pranlukast	13-21	vascular cell adhesion molecule 1	Rattus norvegicus	90-96
15780192-8	2005	CONCLUSION: CysLT1 receptor antagonist ONO-1078 attenuates NMDA-induced brain damage in rats, and this might relate to the attenuation of NMDA receptor-dependent neurotoxicity and the inhibition of the upregulation of VCAM-1 expression.	pranlukast	39-47	cysteinyl leukotriene receptor 1	Rattus norvegicus	12-18
15780192-8	2005	CONCLUSION: CysLT1 receptor antagonist ONO-1078 attenuates NMDA-induced brain damage in rats, and this might relate to the attenuation of NMDA receptor-dependent neurotoxicity and the inhibition of the upregulation of VCAM-1 expression.	pranlukast	39-47	vascular cell adhesion molecule 1	Rattus norvegicus	218-224
15947477-4	2005	The present study evaluates whether pranlukast (an LTRA) modifies eosinophil TEM in response to chemoattractants including PAF and C-C chemokines.	pranlukast	36-46	PCNA clamp associated factor	Homo sapiens	123-126
15947477-10	2005	CONCLUSION: The inhibitory effect of pranlukast on eosinophil transmigration is highly specific for the CysLT1-dependent pathway.	pranlukast	37-47	cysteinyl leukotriene receptor 1	Homo sapiens	104-110
14742305-7	2004	The proportion of CD34(+) cells expressing the eotaxin receptor CC chemokine receptor 3, 24 hours after allergen inhalation, was also reduced by pranlukast.	pranlukast	145-155	CD34 molecule	Homo sapiens	18-22
15241347-4	2004	METHODS: In a randomized, double-blind, crossover study, we examined the effects of 2 weeks of treatment with pranlukast (a cysteinyl leukotriene 1 [CysLT1] receptor antagonist) 300 mg twice daily and placebo on allergen-induced changes in airway responses and circulating dendritic cells in 15 subjects with mild asthma.	pranlukast	110-120	cysteinyl leukotriene receptor 1	Homo sapiens	149-155
15241347-7	2004	RESULTS: Compared with placebo, pranlukast significantly attenuated both the maximum early (by 55%) and the late (by 39%) asthma responses, the allergen-induced methacholine airway hyperresponsiveness, and the increase in macrophage inflammatory protein 1alpha and 3alpha in induced sputum.	pranlukast	32-42	C-C motif chemokine receptor 1	Homo sapiens	222-271
15241347-9	2004	Consistent with this, pranlukast prevented the allergen-induced decrease in CD33+ dendritic cells at 3 hours postallergen (mean Delta from baseline, +4.4%) compared with placebo (mean Delta, -8.4; P <.05), but not CD123+ cells.	pranlukast	22-32	CD33 molecule	Homo sapiens	76-80
15136379-11	2004	CONCLUSIONS: Pranlukast administration decreased airway microvascular permeability through, at least in part, a decrease in airway VEGF levels in steroid-untreated asthmatic patients.	pranlukast	13-23	vascular endothelial growth factor A	Homo sapiens	131-135
15136379-12	2004	However, it is likely that pranlukast administration added little efficacy to inhaled corticosteroid therapy for reduction in airway VEGF levels.	pranlukast	27-37	vascular endothelial growth factor A	Homo sapiens	133-137
15136379-0	2004	Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients.	pranlukast	11-21	vascular endothelial growth factor A	Homo sapiens	40-74
15136379-2	2004	Therefore, this study was designed to examine the effects of pranlukast, a selective leukotriene receptor antagonist, on VEGF levels in induced sputum from steroid-untreated or steroid-treated asthmatic patients.	pranlukast	61-71	vascular endothelial growth factor A	Homo sapiens	121-125
15136379-8	2004	Moreover, VEGF levels in the induced sputum and the airway vascular permeability index also were decreased after pranlukast administration (VEGF levels: before, 5,670 pg/mL [SD, 1,780 pg/mL]; after, 4,380 pg/mL [SD, 1,540 pg/mL]; p = 0.026; airway vascular permeability index: before, 0.032 [SD, 0.012]; after, 0.017 [SD, 0.006]; p = 0.01).	pranlukast	113-123	vascular endothelial growth factor A	Homo sapiens	10-14
15136379-8	2004	Moreover, VEGF levels in the induced sputum and the airway vascular permeability index also were decreased after pranlukast administration (VEGF levels: before, 5,670 pg/mL [SD, 1,780 pg/mL]; after, 4,380 pg/mL [SD, 1,540 pg/mL]; p = 0.026; airway vascular permeability index: before, 0.032 [SD, 0.012]; after, 0.017 [SD, 0.006]; p = 0.01).	pranlukast	113-123	vascular endothelial growth factor A	Homo sapiens	140-144
15136379-9	2004	In addition, the change in airway vascular permeability index from before to after pranlukast administration was significantly correlated with the change in VEGF levels (r = 0.782; p = 0.007).	pranlukast	83-93	vascular endothelial growth factor A	Homo sapiens	157-161
14742305-7	2004	The proportion of CD34(+) cells expressing the eotaxin receptor CC chemokine receptor 3, 24 hours after allergen inhalation, was also reduced by pranlukast.	pranlukast	145-155	C-C motif chemokine ligand 11	Homo sapiens	47-54
15127571-0	2004	[Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats].	pranlukast	22-30	endothelin 1	Rattus norvegicus	105-117
15370959-6	2004	Both pranlukast and zafirlukast showed moderate inhibition of CYP2C9-catalysed tolbutamide 4-methylhydroxylation, competitively inhibiting tolbutamide 4-methylhydroxylation with estimated mean K(i) values of 3.82 +/- 0.50 and 5.86 +/- 0.08 microM, respectively.	pranlukast	5-15	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	62-68
15370959-12	2004	The results suggest that like zafirlukast, pranlukast also has the potential moderately to inhibit CYP2C9-catalysed tolbutamide 4-methylhydroxylation.	pranlukast	43-53	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	99-105
15370959-13	2004	Therefore, the inhibitory potential of pranlukast should be considered when it is co-administered with CYP2C9 substrates with narrow therapeutic ranges (e.g. S-warfarin, phenytoin).	pranlukast	39-49	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	103-109
15127571-1	2004	AIM: To determine the protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats.	pranlukast	43-51	endothelin 1	Rattus norvegicus	126-138
15127571-7	2004	In rats pretreated with ONO-1078, endothelin-1-induced brain edema and brain infarction size were decreased.	pranlukast	24-32	endothelin 1	Rattus norvegicus	34-46
15127571-10	2004	CONCLUSION: ONO-1078 possesses neuroprotective effect against cerebral ischemic injury induced by endothelin-1, therefore, leukotrienes may play a role in the injury of cerebral ischemia.	pranlukast	12-20	endothelin 1	Rattus norvegicus	98-110
14653951-7	2003	ONO-1078 (0.1, 0.3 mg/kg) significantly inhibited the enhanced expression of NMDA receptor subunit protein NR2A in the cortex and VCAM-1 in the hippocampus of ischemic rats.	pranlukast	0-8	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	107-111
14762327-3	2004	Histamine release induced by FMLP and C5a was inhibited by pranlukast in concentration-dependent manner, whereas anti-IgE Ab-induced histamine release was not affected.	pranlukast	59-69	complement C5a receptor 1	Homo sapiens	38-41
14653951-7	2003	ONO-1078 (0.1, 0.3 mg/kg) significantly inhibited the enhanced expression of NMDA receptor subunit protein NR2A in the cortex and VCAM-1 in the hippocampus of ischemic rats.	pranlukast	0-8	vascular cell adhesion molecule 1	Rattus norvegicus	130-136
14653951-8	2003	CONCLUSION: ONO-1078 possesses a neuroprotective effect on global cerebral ischemia in rats, and its mechanism may be partly related to the inhibition of the upregulation of NR2A and VCAM-1 in different regions of the brain.	pranlukast	12-20	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	174-178
14653951-8	2003	CONCLUSION: ONO-1078 possesses a neuroprotective effect on global cerebral ischemia in rats, and its mechanism may be partly related to the inhibition of the upregulation of NR2A and VCAM-1 in different regions of the brain.	pranlukast	12-20	vascular cell adhesion molecule 1	Rattus norvegicus	183-189
12682264-11	2003	The synergistic effect of LTC(4) and IL-13 on eotaxin production was abolished by CysLT1R antagonists pranlukast and montelukast.	pranlukast	102-112	interleukin 13	Homo sapiens	37-42
12801316-11	2003	CONCLUSION: Pranlukast and MK-571 partially inhibited NF-kappa B activation in 1.3% DMSO-differentiated U-937 and Jurkat cells, and IL-6 release in PBMC.	pranlukast	12-22	nuclear factor kappa B subunit 1	Homo sapiens	54-64
12801316-11	2003	CONCLUSION: Pranlukast and MK-571 partially inhibited NF-kappa B activation in 1.3% DMSO-differentiated U-937 and Jurkat cells, and IL-6 release in PBMC.	pranlukast	12-22	interleukin 6	Homo sapiens	132-136
12801316-12	2003	These findings are consistent with the idea that, independently of CysLT1 receptor antagonism, micromolar concentrations of pranlukast suppress the production of proinflammatory cytokines via inhibition of NF-kappa B activation in monocytes/macrophages and T cells, but the contribution of this effect to the anti-inflammatory activity of pranlukast at oral therapeutic doses in asthmatic patients is unclear.	pranlukast	124-134	nuclear factor kappa B subunit 1	Homo sapiens	206-216
12897744-6	2003	Pranlukast-treated mice showed significant attenuation of these changes concomitant with reduction of T(H)2 cytokine and IFN-gamma production by isolated lung mononuclear cells (MNCs).	pranlukast	0-10	interferon gamma	Mus musculus	121-130
12897744-8	2003	Pranlukast also significantly inhibited production of RANTES and activation of nuclear factor kappa B (NF-kappa B) in the isolated lung MNCs.	pranlukast	0-10	chemokine (C-C motif) ligand 5	Mus musculus	54-60
12897744-8	2003	Pranlukast also significantly inhibited production of RANTES and activation of nuclear factor kappa B (NF-kappa B) in the isolated lung MNCs.	pranlukast	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	79-101
12897744-8	2003	Pranlukast also significantly inhibited production of RANTES and activation of nuclear factor kappa B (NF-kappa B) in the isolated lung MNCs.	pranlukast	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	103-113
12801316-0	2003	Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells.	pranlukast	0-10	nuclear factor kappa B subunit 1	Homo sapiens	20-30
12801316-6	2003	The inhibitory effects of pranlukast and MK-571, which is an LTD4 receptor-selective antagonist, on TNF-alpha-induced NF-kappa B activation was evaluated by Western blotting and flow cytometry, and those on lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in peripheral blood mononuclear cells (PBMC) were evaluated by enzyme-linked immunosorbent assaying.	pranlukast	26-36	cysteinyl leukotriene receptor 1	Homo sapiens	61-74
12801316-6	2003	The inhibitory effects of pranlukast and MK-571, which is an LTD4 receptor-selective antagonist, on TNF-alpha-induced NF-kappa B activation was evaluated by Western blotting and flow cytometry, and those on lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in peripheral blood mononuclear cells (PBMC) were evaluated by enzyme-linked immunosorbent assaying.	pranlukast	26-36	tumor necrosis factor	Homo sapiens	100-109
12801316-6	2003	The inhibitory effects of pranlukast and MK-571, which is an LTD4 receptor-selective antagonist, on TNF-alpha-induced NF-kappa B activation was evaluated by Western blotting and flow cytometry, and those on lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in peripheral blood mononuclear cells (PBMC) were evaluated by enzyme-linked immunosorbent assaying.	pranlukast	26-36	nuclear factor kappa B subunit 1	Homo sapiens	118-128
12801316-8	2003	Western blotting demonstrated that 10-5 M pranlukast inhibits NF-kappa B activation in 1.3% DMSO-differentiated U-937 and Jurkat cells by about 40% & 30%, respectively.	pranlukast	42-52	nuclear factor kappa B subunit 1	Homo sapiens	62-72
12801316-9	2003	Flow cytometry demonstrated that pranlukast and MK-571 inhibit NF-kappa B activation in 1.3% DMSO-differentiated U-937 and Jurkat cells in a dose-related manner.	pranlukast	33-43	nuclear factor kappa B subunit 1	Homo sapiens	63-73
12801316-10	2003	Moreover, 10-5 M pranlukast and MK-571 inhibited LPS-induced IL-6 production in PBMC by about 65% and 15%, respectively.	pranlukast	17-27	interleukin 6	Homo sapiens	61-65
12682264-11	2003	The synergistic effect of LTC(4) and IL-13 on eotaxin production was abolished by CysLT1R antagonists pranlukast and montelukast.	pranlukast	102-112	C-C motif chemokine ligand 11	Homo sapiens	46-53
12682264-11	2003	The synergistic effect of LTC(4) and IL-13 on eotaxin production was abolished by CysLT1R antagonists pranlukast and montelukast.	pranlukast	102-112	cysteinyl leukotriene receptor 1	Homo sapiens	82-89
12607939-4	2003	In this model, the CysLT1 receptor antagonist pranlukast suppressed the late-phase nasal blockage but not early blockage and sneezing.	pranlukast	46-56	cysteinyl leukotriene receptor 1	Homo sapiens	19-25
12735786-1	2003	Antileukotrienes are a relatively new class of anti-asthma drugs that either block leukotriene synthesis (5-lipoxygenase inhibitors) like zileuton, or antagonise the most relevant of their receptors (the cysteinyl leukotriene 1 receptor [CysLT1]) like montelukast, zafirlukast or pranlukast.	pranlukast	280-290	cysteinyl leukotriene receptor 1	Homo sapiens	204-236
12373000-11	2002	CysLTs induced an increase in intracellular free Ca(2+) in eosinophils via CysLT(1), as suggested by the efficient inhibition by a CysLT(1) antagonist, pranlukast, in addition to the rank order of potency being LTD(4), LTC(4) and LTE(4).	pranlukast	152-162	cysteinyl leukotriene receptor 1	Homo sapiens	75-83
11854273-6	2002	Pranlukast, a specific inhibitor for human CysLT(1), antagonized mCysLT(2) responses as determined by Ca(2+) elevation and receptor-induced promoter activation.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Homo sapiens	43-51
12360108-6	2002	Univariate analysis demonstrated that the better response to pranlukast (more than 10% improvement of FEV(1) ) was correlated with LTC(4) S genotype (P < 0.01) and pretreatment airway reversibility to salbutamol (P < 0.01), but not with sex, age, atopic status, urinary leukotriene E(4) excretion rate, or daily dose of inhaled corticosteroid.	pranlukast	61-71	leukotriene C4 synthase	Homo sapiens	131-139
11264758-2	2001	Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor.	pranlukast	0-10	cysteinyl leukotriene receptor 1	Homo sapiens	59-65
11972613-11	2002	Increased IL-5 activity in the serum was inhibited by both pranlukast and MCI-826 by over 90%.	pranlukast	59-69	interleukin-5	Cavia porcellus	10-14
11796443-10	2002	Pranlukast suppressed the fall in FEV(1) both during IAR and LAR (73.8% and 51.9%, respectively) and inhibited the increase in sputum eosinophil count during LAR and sputum ECP during IAR and LAR.	pranlukast	0-10	ribonuclease A family member 3	Homo sapiens	173-176
11527250-0	2001	Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma.	pranlukast	11-21	cysteinyl leukotriene receptor 1	Homo sapiens	25-57
11527250-2	2001	OBJECTIVE: To investigate the effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, in patients with moderate/severe asthma, when combined with beclomethasone dipropionate (BDP).	pranlukast	41-51	cysteinyl leukotriene receptor 1	Homo sapiens	55-87
11796443-12	2002	Pranlukast suppressed IAR and inhibited the increase of the level of sputum ECP, but failed to change aspirin-induced LT production in the sputum and urine.	pranlukast	0-10	ribonuclease A family member 3	Homo sapiens	76-79
11595704-12	2001	Multidrug resistance-reversing agents, such as ONO-1078 and MK571, that directly interact and inhibit the transporting activity of MRP1 may be useful for treating ATL patients.	pranlukast	47-55	ATP binding cassette subfamily C member 1	Homo sapiens	131-135
11511299-7	2001	In contrast, a leukotriene receptor antagonist, ONO-1078, specifically suppressed Th2-induced inflammation.	pranlukast	48-56	heart and neural crest derivatives expressed 2	Mus musculus	82-85
11476469-6	2001	Pranlukast inhibited the bronchial reaction and an increase in sputum ECP after threshold dosed of ASA, but failed to change aspirin-induced LT production in sputum and urine.	pranlukast	0-10	ribonuclease A family member 3	Homo sapiens	70-73
11264758-9	2001	Pranlukast significantly reduced the consumption of beta2-agonist.	pranlukast	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	52-57
10848924-8	2000	RESULTS: After the 4 weeks of treatment with pranlukast, patients" symptoms, blood eosinophils, serum ECP, sputum eosinophils, and sputum ECP were significantly decreased.	pranlukast	45-55	ribonuclease A family member 3	Homo sapiens	102-105
10996024-5	2000	Namely, the challenge with OA plus C5a resulted in a higher IAR than OA plus ZAS, and also caused an early animal death up to 6 h, which was prevented by a combined pretreatment with pranlukast and the H(1) receptor antagonist, diphenhydramine.A histological examination at 6 h after the OA challenge identified an infiltration of inflammatory cells into the bronchial submucosal tissue, with a predominance of neutrophils and fewer eosinophils.	pranlukast	183-193	complement C5	Rattus norvegicus	35-38
10848924-8	2000	RESULTS: After the 4 weeks of treatment with pranlukast, patients" symptoms, blood eosinophils, serum ECP, sputum eosinophils, and sputum ECP were significantly decreased.	pranlukast	45-55	ribonuclease A family member 3	Homo sapiens	138-141
10887942-5	2000	Although the potency of pranlukast for LTD4 receptor antagonism (ED50 = 0.34 mg/kg) is greater than that of YM158 (ED50 = 8.6 mg/kg), the doses of both pranlukast and YM158 for significant inhibition of the antigen-evoked airway response were the same, indicating that the TXA2 receptor antagonism of YM158 plays an important role in its anti-asthmatic effects.	pranlukast	24-34	cysteinyl leukotriene receptor 1	Homo sapiens	39-52
10773010-11	2000	In conclusion, pranlukast inhibits LAR, BAL eosinophilia, and Interleukin-5 expression in rats with adoptively transferred LAR, indicating an important role for cys LTs in these T cell-driven responses.	pranlukast	15-25	interleukin 5	Rattus norvegicus	62-75
10773010-10	2000	Interleukin-5 mRNA-positive cells were diminished by 50% in pranlukast-treated animals.	pranlukast	60-70	interleukin 5	Rattus norvegicus	0-13
10753671-8	2000	MK-571 and ONO-1078, reversing agents for MRP1-mediated MDR, considerably inhibited the transport of LTC(4) by both YCF1 and MRP1.	pranlukast	11-19	ATP-binding cassette glutathione S-conjugate transporter YCF1	Saccharomyces cerevisiae S288C	116-120
10520082-11	1999	These findings indicate that ONO-1078 suppresses the production of IL-4 (a cytokine that affects IgG antibody production), IL-5, and GM-CSF (cytokines that affect eosinophil activation) by peripheral blood mononuclear cells under stimulation with specific antigens in patients with bronchial asthma.	pranlukast	29-37	interleukin 4	Homo sapiens	67-71
10804983-0	1999	Pranlukast, a cysteinyl leukotriene antagonist, reduces serum eosinophil cationic protein levels in patients with asthma.	pranlukast	0-10	ribonuclease A family member 3	Homo sapiens	62-89
10804983-2	1999	We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients.	pranlukast	28-38	ribonuclease A family member 3	Homo sapiens	123-150
10520082-11	1999	These findings indicate that ONO-1078 suppresses the production of IL-4 (a cytokine that affects IgG antibody production), IL-5, and GM-CSF (cytokines that affect eosinophil activation) by peripheral blood mononuclear cells under stimulation with specific antigens in patients with bronchial asthma.	pranlukast	29-37	interleukin 5	Homo sapiens	123-127
10520082-11	1999	These findings indicate that ONO-1078 suppresses the production of IL-4 (a cytokine that affects IgG antibody production), IL-5, and GM-CSF (cytokines that affect eosinophil activation) by peripheral blood mononuclear cells under stimulation with specific antigens in patients with bronchial asthma.	pranlukast	29-37	colony stimulating factor 2	Homo sapiens	133-139
10462554-1	1999	The cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory disorders, in particular asthma, for which the CysLT receptor antagonists pranlukast, zafirlukast, and montelukast, have been introduced recently as novel therapeutics.	pranlukast	170-180	cysteinyl leukotriene receptor 1	Homo sapiens	143-157
10430730-5	1999	Both pranlukast and SB210661 significantly attenuated BHR induced by eotaxin with logPC(50), which is the concentration of acetylcholine needed to increase baseline insufflation pressure by 50%, from -0.43 +/- 0.16 to 0.39 +/- 0.10 and from -0.22 +/- 0.10 to 0.53 +/- 0.10, respectively (p < 0.05).	pranlukast	5-15	chemokine (C-C motif) ligand 11	Mus musculus	69-76
10462554-5	1999	[(3)H]LTD(4) binding and LTD(4)-induced calcium mobilization in HEK-293 cells expressing the CysLT receptor were potently inhibited by the structurally distinct CysLTR antagonists pranlukast, montelukast, zafirlukast, and pobilukast; the rank order potency was pranlukast = zafirlukast > montelukast > pobilukast.	pranlukast	261-271	cysteinyl leukotriene receptor 1	Homo sapiens	93-107
10462554-5	1999	[(3)H]LTD(4) binding and LTD(4)-induced calcium mobilization in HEK-293 cells expressing the CysLT receptor were potently inhibited by the structurally distinct CysLTR antagonists pranlukast, montelukast, zafirlukast, and pobilukast; the rank order potency was pranlukast = zafirlukast > montelukast > pobilukast.	pranlukast	180-190	cysteinyl leukotriene receptor 1	Homo sapiens	93-107
10462554-5	1999	[(3)H]LTD(4) binding and LTD(4)-induced calcium mobilization in HEK-293 cells expressing the CysLT receptor were potently inhibited by the structurally distinct CysLTR antagonists pranlukast, montelukast, zafirlukast, and pobilukast; the rank order potency was pranlukast = zafirlukast > montelukast > pobilukast.	pranlukast	261-271	cysteinyl leukotriene receptor 1	Homo sapiens	161-167
10462554-5	1999	[(3)H]LTD(4) binding and LTD(4)-induced calcium mobilization in HEK-293 cells expressing the CysLT receptor were potently inhibited by the structurally distinct CysLTR antagonists pranlukast, montelukast, zafirlukast, and pobilukast; the rank order potency was pranlukast = zafirlukast > montelukast > pobilukast.	pranlukast	180-190	cysteinyl leukotriene receptor 1	Homo sapiens	161-167
9751271-2	1998	We examined the effect of ONO-1078 on the sensitivity to vincristine (VCR) of MRP overexpressing multidrug-resistant CV60 and its parental drug-sensitive KB-3-1 cell lines.	pranlukast	26-34	ATP binding cassette subfamily C member 1	Homo sapiens	78-81
10385593-6	1999	LT production and p38-MAPK phosphorylation were required for induction of apoptosis because thiol depletion-induced apoptosis was completely blocked by the 5-lipoxygenase inhibitor AA861, the LT antagonists FPL55712 and ONO1078, and the p38-MAPK inhibitor SB203580.	pranlukast	220-227	arachidonate 5-lipoxygenase	Homo sapiens	156-170
9840083-5	1998	RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients.	pranlukast	106-116	alkaline phosphatase, placental	Homo sapiens	27-47
9840083-5	1998	RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients.	pranlukast	106-116	alkaline phosphatase, placental	Homo sapiens	49-52
9751271-1	1998	The leukotriene D4 (LTD4) receptor antagonist, 4-oxo-8-[p-(4-phenylbutyloxy)benzoylamino]-2-(tetrazol-5-yl) -4H-1-benzopyran hemihydrate (ONO-1078) is used for the treatment of allergic asthma and other immediate hypersensitivity diseases.	pranlukast	138-146	cysteinyl leukotriene receptor 1	Homo sapiens	4-34
10391245-3	1999	The CysLT1-selective antagonists, such as montelukast (Singulair), zafirlukast (Accolate) and pranlukast (Onon), are important in the treatment of asthma.	pranlukast	94-104	cysteinyl leukotriene receptor 1	Homo sapiens	4-10
10391245-3	1999	The CysLT1-selective antagonists, such as montelukast (Singulair), zafirlukast (Accolate) and pranlukast (Onon), are important in the treatment of asthma.	pranlukast	106-110	cysteinyl leukotriene receptor 1	Homo sapiens	4-10
10478608-6	1999	CysLT1 antagonists, currently on the pharmaceutical market in some countries, are zafirlukast (Accolate), pranlukast (Ultair, Onon), and montelukast (Singulair).	pranlukast	106-116	cysteinyl leukotriene receptor 1	Homo sapiens	0-6
10028377-0	1999	Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma.	pranlukast	11-21	ribonuclease A family member 3	Homo sapiens	39-66
9934474-1	1998	A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).	pranlukast	189-199	cysteinyl leukotriene receptor 1	Homo sapiens	16-22
9790952-0	1998	A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein.	pranlukast	35-43	ATP binding cassette subfamily C member 1	Homo sapiens	130-158
9790952-1	1998	ONO-1078 is a new class of peptide leukotriene receptor antagonist, and multidrug resistance protein (MRP) is a membrane tranporter of multiple anticancer drugs and endogenous leukotriene C4 (LTC4).	pranlukast	0-8	ATP binding cassette subfamily C member 1	Homo sapiens	102-105
9790952-4	1998	The effect of ONO-1078 on MRP-mediated calcein-efflux was determined by flow cytometry.	pranlukast	14-22	ATP binding cassette subfamily C member 1	Homo sapiens	26-29
9790952-7	1998	Our findings indicate that ONO-1078 modulates multidrug resistance and inhibits LTC4-efflux in lung cancer cells, by inhibition of MRP function.	pranlukast	27-35	ATP binding cassette subfamily C member 1	Homo sapiens	131-134
9751271-4	1998	The VCR sensitivity of multidrug-resistant KB-C2 cells that overexpressed P-gp was increased 2.6-fold by ONO-1078.	pranlukast	105-113	phosphoglycolate phosphatase	Homo sapiens	74-78
9751271-8	1998	These findings suggest that ONO-1078 inhibits the transporting activity of MRP and that ONO-1078 increases the sensitivity to VCR of KB-3-1 cells by increasing the VCR uptake in the cells.	pranlukast	28-36	ATP binding cassette subfamily C member 1	Homo sapiens	75-78
9372685-5	1997	The PAF-elicited bronchoconstriction in the transgenic mice was significantly reduced not only by a PAF receptor antagonist (WEB-2086) but also by a thromboxane synthesis inhibitor (indomethacin or ozagrel), an inhibitor of 5-lipoxygenase-activating protein (MK-886), or a cysteinyl leukotriene (LT) antagonist (pranlukast).	pranlukast	312-322	patchy fur	Mus musculus	4-7
10193369-7	1998	RESULTS: When the pranlukast and placebo treated groups were compared there were decreases in beta 2 agonist use, symptom score, and airway methacholine responsiveness after pranlukast but no increase in FEV1 was seen.	pranlukast	18-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	94-100
9227717-12	1997	CONCLUSIONS: This study shows that pranlukast is a potent and selective LTD4 receptor antagonist in humans which blocks LTD4 challenge after initial and repeated administration when given twice daily for five days.	pranlukast	35-45	cysteinyl leukotriene receptor 1	Homo sapiens	72-85
9411661-7	1997	Two antagonists of CysLT1 receptors have been recently launched on the market: ONO-1078, pranlukast, Onon and ICI-204,219, zafirlukast, Accolate.	pranlukast	79-87	cysteinyl leukotriene receptor 1	Homo sapiens	19-25
9411661-7	1997	Two antagonists of CysLT1 receptors have been recently launched on the market: ONO-1078, pranlukast, Onon and ICI-204,219, zafirlukast, Accolate.	pranlukast	89-99	cysteinyl leukotriene receptor 1	Homo sapiens	19-25
8950936-3	1996	In brittle asthmatics regularly treated with a long-acting beta 2-agonist and a sustained-release theophylline, an oral cysteinyl leukotriene antagonist, pranlukast, almost completely inhibited a chaotic pattern of PEF readings.	pranlukast	154-164	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	59-65
9152370-6	1997	Expression of endothelial P-selectin induced by either LTC4 or LTD4 was not blocked however by pretreatment of HUVEC with the selective cysteinyl leukotriene-1 (CysLT1) receptor antagonists SKF 104353, pranlukast or zafirlukast before agonist exposure.	pranlukast	202-212	selectin P	Homo sapiens	26-36
9150842-5	1997	Results from clinical studies using receptor antagonists, such as LY-171883, SK&F-104353, ICI-204219, ONO-1078, MK-751, MK-0679, demonstrate beneficial effects, with improvement in symptoms and forced expiratory volume in one second (FEV1), and a reduction in the use of beta 2-adrenergic relief medication.	pranlukast	106-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	275-281
8887574-8	1996	Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO-1078, SB 205312) (20 mg/kg, intragastrically), significantly inhibited both the bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on either parameter.	pranlukast	48-58	cysteinyl leukotriene receptor 1	Cavia porcellus	22-35
8887574-8	1996	Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO-1078, SB 205312) (20 mg/kg, intragastrically), significantly inhibited both the bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on either parameter.	pranlukast	60-68	cysteinyl leukotriene receptor 1	Cavia porcellus	22-35
8887574-8	1996	Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO-1078, SB 205312) (20 mg/kg, intragastrically), significantly inhibited both the bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on either parameter.	pranlukast	70-79	cysteinyl leukotriene receptor 1	Cavia porcellus	22-35
34050048-0	2021	Elevated Prothrombin Time and International Normalized Ratio Caused by Drug-Drug Interactions Between Warfarin and Pranlukast.	pranlukast	115-125	coagulation factor II, thrombin	Homo sapiens	9-20
8979306-7	1996	In order to investigate the inhibitory mechanism of ONO-1078, the effect on the LPS-induced production of tumor necrosis factor (TNF) was examined.	pranlukast	52-60	tumor necrosis factor	Cavia porcellus	106-127
8979306-13	1996	These results suggest that TNF plays an important role in the onset of LPS-induced bronchial hyper-reactivity, and that ONO-1078 inhibits the LPS-induced airway hyperreactivity probably due to the inhibition of TNF production.	pranlukast	120-128	tumor necrosis factor	Cavia porcellus	211-214
34222850-10	2021	Pranlukast inhibited HBV preS1 binding, whereas cytochalasin D prevented the internalisation of HBV.	pranlukast	0-10	large envelope protein;middle envelope protein;small envelope protein	Hepatitis B virus	25-30
35268621-9	2022	Predicted human protein interactors of pranlukast-treated Mtb metabolome were identified in association with autophagy, inflammation, DNA repair, and other immune-related processes.	pranlukast	39-49	metallothionein 1J, pseudogene	Homo sapiens	58-61
35268621-11	2022	This study facilitates the understanding of pranlukast-mediated metabolic changes in Mtb and holds the potential to identify novel therapeutic approaches using metabolic pathways in Mtb.	pranlukast	44-54	metallothionein 1J, pseudogene	Homo sapiens	85-88
35268621-11	2022	This study facilitates the understanding of pranlukast-mediated metabolic changes in Mtb and holds the potential to identify novel therapeutic approaches using metabolic pathways in Mtb.	pranlukast	44-54	metallothionein 1J, pseudogene	Homo sapiens	182-185
8990528-4	1996	ONO-1078, 10(-5) M, also inhibited ECP release of eosinophils obtained from both asthma patients and normal subjects.	pranlukast	0-8	ribonuclease A family member 3	Homo sapiens	35-38
8990528-5	1996	We think that ONO-1078 may have another pharmacological effect to prevent the activation of human peripheral blood eosinophils by inhibiting LTC4 and ECP release.	pranlukast	14-22	ribonuclease A family member 3	Homo sapiens	150-153
7842366-7	1994	The LTC4 and LTD4 receptor antagonist ONO-1078 inhibited these effects of LTC4 and LTD4, suggesting LTC4 and LTD4 may induce airway wall thickening and airway hyperresponsiveness through LTC4 and LTD4 receptors in the airways.	pranlukast	38-46	cysteinyl leukotriene receptor 1	Cavia porcellus	13-26
7514876-2	1994	The clinical effect of a new leukotriene antagonist, ONO 1078 (4-oxo-8-[4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H- 1-benzopyran hemihydrate, CAS 103177-37-3) on symptoms, pulmonary lung function and bronchial hyperresponsiveness was evaluated in patients with bronchial asthma.	pranlukast	53-61	BCAR1 scaffold protein, Cas family member	Homo sapiens	149-152
1416420-5	1992	In the presence of l-serine borate complex, which inhibits the conversion of LTC4 to LTD4 by gamma-glutamyl transpeptidase, ONO-1078 significantly inhibited the LTC4-induced contraction, suggesting that ONO-1078 is an antagonist of both LTC4 and LTD4.	pranlukast	124-132	inactive glutathione hydrolase 2	Homo sapiens	93-122
1416420-5	1992	In the presence of l-serine borate complex, which inhibits the conversion of LTC4 to LTD4 by gamma-glutamyl transpeptidase, ONO-1078 significantly inhibited the LTC4-induced contraction, suggesting that ONO-1078 is an antagonist of both LTC4 and LTD4.	pranlukast	203-211	inactive glutathione hydrolase 2	Homo sapiens	93-122
35490268-7	2022	The combination of the loratadine, fluticasone, and pranlukast can effectively control the symptoms of AR probably via modulating several related mechanisms at early and late phases of allergic responses.	pranlukast	52-62	ferredoxin reductase	Mus musculus	103-105
32330496-3	2020	The CysLT1R is a validated target for treatment of pulmonary diseases and several selective antagonists for this receptor, including montelukast, zafirlukast and pranlukast, have shown effective in the management of asthma.	pranlukast	162-172	cysteinyl leukotriene receptor 1	Homo sapiens	4-11
32805694-0	2020	Inhibition of GPR17 with pranlukast protects against TNF-alpha-induced loss of type II collagen in ATDC5 cells.	pranlukast	25-35	G protein-coupled receptor 17	Mus musculus	14-19
32805694-0	2020	Inhibition of GPR17 with pranlukast protects against TNF-alpha-induced loss of type II collagen in ATDC5 cells.	pranlukast	25-35	tumor necrosis factor	Mus musculus	53-62
32805694-7	2020	We also found that antagonism of GPR17 with pranlukast significantly inhibited oxidative stress by downregulating the intracellular level of reactive oxygen species (ROS) and increasing the activity of super oxide dismutase (SOD) against TNF-alpha.	pranlukast	44-54	G protein-coupled receptor 17	Mus musculus	33-38
32805694-7	2020	We also found that antagonism of GPR17 with pranlukast significantly inhibited oxidative stress by downregulating the intracellular level of reactive oxygen species (ROS) and increasing the activity of super oxide dismutase (SOD) against TNF-alpha.	pranlukast	44-54	tumor necrosis factor	Mus musculus	238-247
32805694-8	2020	Interestingly, treatment with pranlukast prevented TNF-alpha-induced reduction of type II collagen.	pranlukast	30-40	tumor necrosis factor	Mus musculus	51-60
32805694-11	2020	Pranlukast also prevented the activation of the JAK2/STAT1/IRF-1 signaling pathway, thereby suppressing the expression of pro-inflammatory cytokines and enzymes.	pranlukast	0-10	Janus kinase 2	Mus musculus	48-52
32805694-11	2020	Pranlukast also prevented the activation of the JAK2/STAT1/IRF-1 signaling pathway, thereby suppressing the expression of pro-inflammatory cytokines and enzymes.	pranlukast	0-10	signal transducer and activator of transcription 1	Mus musculus	53-58
32805694-11	2020	Pranlukast also prevented the activation of the JAK2/STAT1/IRF-1 signaling pathway, thereby suppressing the expression of pro-inflammatory cytokines and enzymes.	pranlukast	0-10	interferon regulatory factor 1	Mus musculus	59-64
32805694-12	2020	Furthermore, pranlukast rescued TNF-alpha-induced reduced SOX-9 expression.	pranlukast	13-23	tumor necrosis factor	Mus musculus	32-41
32805694-12	2020	Furthermore, pranlukast rescued TNF-alpha-induced reduced SOX-9 expression.	pranlukast	13-23	SRY (sex determining region Y)-box 9	Mus musculus	58-63
31564414-4	2019	A cell-based thallium flux assay was developed and used to screen a library of drug-like molecules, from which we identified the CysLT1 antagonist Pranlukast as a novel activator of TREK2.	pranlukast	147-157	cysteinyl leukotriene receptor 1	Homo sapiens	129-135
32494122-12	2020	Results: Pranlukast, a drug used to treat asthma, bound to CD49f in silico and inhibited the adhesion of CD49f+ MDA-MB-231 cells to laminin, indicating that it antagonizes CD49f-containing integrins.	pranlukast	9-19	integrin subunit alpha 6	Homo sapiens	59-64
32494122-12	2020	Results: Pranlukast, a drug used to treat asthma, bound to CD49f in silico and inhibited the adhesion of CD49f+ MDA-MB-231 cells to laminin, indicating that it antagonizes CD49f-containing integrins.	pranlukast	9-19	integrin subunit alpha 6	Homo sapiens	105-110
32494122-12	2020	Results: Pranlukast, a drug used to treat asthma, bound to CD49f in silico and inhibited the adhesion of CD49f+ MDA-MB-231 cells to laminin, indicating that it antagonizes CD49f-containing integrins.	pranlukast	9-19	integrin subunit alpha 6	Homo sapiens	105-110
32494122-13	2020	Molecular dynamics analysis showed that pranlukast binding induces conformational changes in CD49f that affect its interaction with beta1-integrin subunit and constrained the conformational dynamics of the heterodimer.	pranlukast	40-50	integrin subunit alpha 6	Homo sapiens	93-98
32494122-13	2020	Molecular dynamics analysis showed that pranlukast binding induces conformational changes in CD49f that affect its interaction with beta1-integrin subunit and constrained the conformational dynamics of the heterodimer.	pranlukast	40-50	integrin subunit beta 1	Homo sapiens	132-146
32494122-15	2020	Brief exposure of MDA-MB-231 cells to pranlukast altered CD49f-dependent signaling, reducing focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) activation.	pranlukast	38-48	integrin subunit alpha 6	Homo sapiens	57-62
32494122-15	2020	Brief exposure of MDA-MB-231 cells to pranlukast altered CD49f-dependent signaling, reducing focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) activation.	pranlukast	38-48	protein tyrosine kinase 2	Homo sapiens	93-114
32494122-15	2020	Brief exposure of MDA-MB-231 cells to pranlukast altered CD49f-dependent signaling, reducing focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) activation.	pranlukast	38-48	protein tyrosine kinase 2	Homo sapiens	116-119
32494122-15	2020	Brief exposure of MDA-MB-231 cells to pranlukast altered CD49f-dependent signaling, reducing focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) activation.	pranlukast	38-48	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	125-154
32494122-16	2020	Further, pranlukast-treated cells showed decreased CD44 and SOX2 expression, SOX2 promoter transactivation, and in vivo tumorigenicity, supporting that this drug reduces the frequency of CSC.	pranlukast	9-19	CD44 molecule (Indian blood group)	Homo sapiens	51-55
32494122-16	2020	Further, pranlukast-treated cells showed decreased CD44 and SOX2 expression, SOX2 promoter transactivation, and in vivo tumorigenicity, supporting that this drug reduces the frequency of CSC.	pranlukast	9-19	SRY-box transcription factor 2	Homo sapiens	60-64
32494122-16	2020	Further, pranlukast-treated cells showed decreased CD44 and SOX2 expression, SOX2 promoter transactivation, and in vivo tumorigenicity, supporting that this drug reduces the frequency of CSC.	pranlukast	9-19	SRY-box transcription factor 2	Homo sapiens	77-81
32494122-17	2020	Conclusion: Our results support the function of pranlukast as a CD49f antagonist that reduces the CSC population in triple-negative breast cancer cells.	pranlukast	48-58	integrin subunit alpha 6	Homo sapiens	64-69
31564414-0	2019	Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2.	pranlukast	0-10	potassium two pore domain channel subfamily K member 10	Homo sapiens	88-93
31564414-4	2019	A cell-based thallium flux assay was developed and used to screen a library of drug-like molecules, from which we identified the CysLT1 antagonist Pranlukast as a novel activator of TREK2.	pranlukast	147-157	potassium two pore domain channel subfamily K member 10	Homo sapiens	182-187
31564414-11	2019	Pranlukast therefore represents a novel tool by which to study the mechanism of TREK2 activation.	pranlukast	0-10	potassium two pore domain channel subfamily K member 10	Homo sapiens	80-85
31390227-0	2019	CysLT1 receptor antagonists Pranlukast and Zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor.	pranlukast	28-38	cysteinyl leukotriene receptor 1	Homo sapiens	0-6
31390227-0	2019	CysLT1 receptor antagonists Pranlukast and Zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor.	pranlukast	28-38	leucine rich repeat containing 8 VRAC subunit A	Homo sapiens	63-68
31390227-3	2019	We discovered the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, Pranlukast, as a novel inhibitor of endogenous VRAC expressed in HEK293 cells.	pranlukast	73-83	cysteinyl leukotriene receptor 1	Homo sapiens	18-50
31390227-3	2019	We discovered the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, Pranlukast, as a novel inhibitor of endogenous VRAC expressed in HEK293 cells.	pranlukast	73-83	cysteinyl leukotriene receptor 1	Homo sapiens	52-59
31390227-10	2019	Our data suggest that both Pranlukast and Zafirlukast are likely direct channel inhibitors that work independently of the CysLT1R.	pranlukast	27-37	cysteinyl leukotriene receptor 1	Homo sapiens	122-129
28112182-5	2017	Knockdown of hippocampal CysLT1R or blockade of CysLT1R by pretreatment with pranlukast (0.5 mg/kg, ip) significantly suppressed LPS-induced depressive behaviors, as evidenced by decreases in mouse immobility time in the forced swimming test (FST) and tail suspension test (TST) and latency to feed in the novelty-suppressed feeding (NSF) test.	pranlukast	77-87	cysteinyl leukotriene receptor 1	Mus musculus	48-55
30353976-0	2018	Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.	pranlukast	26-36	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	50-60
30353976-3	2018	We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1 R) antagonist pranlukast on the farnesoid X receptor (FXR).	pranlukast	102-112	cysteinyl leukotriene receptor 1	Homo sapiens	47-79
30353976-3	2018	We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1 R) antagonist pranlukast on the farnesoid X receptor (FXR).	pranlukast	102-112	cysteinyl leukotriene receptor 1	Homo sapiens	81-89
30353976-3	2018	We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1 R) antagonist pranlukast on the farnesoid X receptor (FXR).	pranlukast	102-112	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	130-140
30353976-3	2018	We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1 R) antagonist pranlukast on the farnesoid X receptor (FXR).	pranlukast	102-112	nuclear receptor subfamily 1 group H member 4	Homo sapiens	142-145
30146807-12	2018	CONCLUSIONS: : CysLTR antagonists Pranlukast and HAMI 3379 have long-term neuroprotective effect on chronic brain injury induced by global cerebral ischemia/reperfusion in gerbils.	pranlukast	34-44	cysteinyl leukotriene receptor 1	Homo sapiens	15-21
31188588-2	2019	We report here two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified by molecular docking-based virtual screening.	pranlukast	67-77	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	19-24
31188588-5	2019	Abnormalities in autophagy markers p62 and LC3B-II were alleviated by ezetimibe and pranlukast.	pranlukast	84-94	nucleoporin 62	Homo sapiens	35-38
31188588-6	2019	Combined treatment of recombinant GALNS with ezetimibe or pranlukast produced an additive effect.	pranlukast	58-68	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	34-39
31188588-7	2019	Altogether, the results demonstrate that ezetimibe and pranlukast can increase the yield of recombinant GALNS and be used as a monotherapy or combination therapy to improve the therapeutic efficacy of MPS IVA enzyme replacement therapy.	pranlukast	55-65	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	104-109
30949053-4	2019	Montelukast, pranlukast and zafirlukast inhibited human sEH with IC50 values of 1.9, 14.1, and 0.8 muM, respectively.	pranlukast	13-23	epoxide hydrolase 2	Homo sapiens	56-59
29031615-0	2018	The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling.	pranlukast	36-46	transforming growth factor beta 1	Homo sapiens	91-99
29031615-10	2018	We further demonstrated that pranlukast not only inhibited transforming growth factor-beta 1 (TGF-beta1)-induced Smad signaling in human fetal lung fibroblast cells but also simultaneously reduced collagen synthesis and pro-fibrotic gene expression.	pranlukast	29-39	transforming growth factor beta 1	Homo sapiens	59-92
29031615-10	2018	We further demonstrated that pranlukast not only inhibited transforming growth factor-beta 1 (TGF-beta1)-induced Smad signaling in human fetal lung fibroblast cells but also simultaneously reduced collagen synthesis and pro-fibrotic gene expression.	pranlukast	29-39	transforming growth factor beta 1	Homo sapiens	94-103
29031615-11	2018	CONCLUSIONS: The leukotriene receptor antagonist pranlukast can reduce airway inflammation and remodeling by inhibiting TGF-beta/Smad signaling in an OVA-sensitized and -challenged asthma mouse model, thus suppressing AHR.	pranlukast	49-59	transforming growth factor beta 1	Homo sapiens	120-128
27810377-3	2017	shRNA-mediated knockdown or pharmacological blockade (by pranlukast) of CysLT1R were performed in ICR mice for 21days prior to systemic infusion of LPS.	pranlukast	57-67	cysteinyl leukotriene receptor 1	Mus musculus	72-79
27720931-1	2017	Our previous studies showed that cysteinyl leukotrienes receptor 1 (CysLT1R) is upregulated in amyloid-beta (Abeta)-induced neurotoxicity and that administration of CysLT1R antagonists such as pranlukast or montelukast can ameliorate memory impairment in mice.	pranlukast	193-203	cysteinyl leukotriene receptor 1	Mus musculus	68-75
27720931-1	2017	Our previous studies showed that cysteinyl leukotrienes receptor 1 (CysLT1R) is upregulated in amyloid-beta (Abeta)-induced neurotoxicity and that administration of CysLT1R antagonists such as pranlukast or montelukast can ameliorate memory impairment in mice.	pranlukast	193-203	cysteinyl leukotriene receptor 1	Mus musculus	165-172
27810377-6	2017	However, shRNA-mediated knockdown or pranlukast-treated blockade of CysLT1R improved performance of the mice in these tests.	pranlukast	37-47	cysteinyl leukotriene receptor 1	Mus musculus	68-75
26385352-2	2015	By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis.	pranlukast	131-141	cysteinyl leukotriene receptor 1	Homo sapiens	45-51
27146207-0	2016	Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein.	pranlukast	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	44-48
27146207-2	2016	RESULTS: NMR and fluorescence experiments demonstrated hRKIP could bind pranlukast with a binding constant of 1016 mM(-1).	pranlukast	72-82	phosphatidylethanolamine binding protein 1	Homo sapiens	55-60
27146207-4	2016	Furthermore, 25 muM pranlukast could up-regulate the ERK phosphorylation by about 17 %.	pranlukast	20-30	mitogen-activated protein kinase 1	Homo sapiens	53-56
27146207-5	2016	CONCLUSION: Pranlukast may be used as a potential drug precursor for treating hRKIP involved diseases.	pranlukast	12-22	phosphatidylethanolamine binding protein 1	Homo sapiens	78-83
26807587-5	2016	By using a repositioning analysis based on systems biology approach (TPMS technology), we identified and validated the neuroprotective potential of two new drug combinations: Aliretinoin and Pranlukast, and Aliretinoin and Mefloquine.	pranlukast	191-201	trichoplein keratin filament binding	Homo sapiens	69-73
27115997-5	2016	Furthermore, we have revealed that the novel radioactive CysLT1R antagonist [3H]-pranlukast bound specifically to CysLT1R in human inferior turbinates and its binding sites were localized to vascular endothelium and the interstitial cells.	pranlukast	81-91	cysteinyl leukotriene receptor 1	Homo sapiens	57-64
27115997-5	2016	Furthermore, we have revealed that the novel radioactive CysLT1R antagonist [3H]-pranlukast bound specifically to CysLT1R in human inferior turbinates and its binding sites were localized to vascular endothelium and the interstitial cells.	pranlukast	81-91	cysteinyl leukotriene receptor 1	Homo sapiens	114-121
27733608-7	2016	Similarly, pharmacological inhibition of Gpr17 with pranlukast promoted remyelination.	pranlukast	52-62	G protein-coupled receptor 17	Mus musculus	41-46
25839425-5	2015	We also demonstrate here that the CysLT1R antagonist zafirlukast, pranlukast, pobilukast and iralukast also possess CysLT2R antagonistic activity, which could help in reconsidering previous data on the role of cysteinyl-LTs in the cardiovascular system.	pranlukast	66-76	cysteinyl leukotriene receptor 1	Homo sapiens	34-41
25839425-5	2015	We also demonstrate here that the CysLT1R antagonist zafirlukast, pranlukast, pobilukast and iralukast also possess CysLT2R antagonistic activity, which could help in reconsidering previous data on the role of cysteinyl-LTs in the cardiovascular system.	pranlukast	66-76	cysteinyl leukotriene receptor 2	Homo sapiens	116-123
25395620-5	2015	Pharmacological blockade of CysLT1Rs with pranlukast significantly reduced myogenic tone not only in AT1A/1B (-/-) but also in wild-type arteries.	pranlukast	42-52	cysteinyl leukotriene receptor 1	Mus musculus	28-34
25681271-11	2015	In comparison, the CysLT1R antagonist pranlukast did not affect microglial activation and IFN-gamma release, but inhibited astrocyte proliferation and reduced serum IL-4.	pranlukast	38-48	interleukin 4	Rattus norvegicus	165-169
25395620-5	2015	Pharmacological blockade of CysLT1Rs with pranlukast significantly reduced myogenic tone not only in AT1A/1B (-/-) but also in wild-type arteries.	pranlukast	42-52	angiotensin II receptor, type 1a	Mus musculus	101-105
24360935-8	2014	Interestingly, pranlukast enhanced AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta) with consequent activation of acetyl-CoA carboxylase (ACC) and suppression of mammalian target of rapamycin (mTOR) pathway.	pranlukast	15-25	mechanistic target of rapamycin kinase	Homo sapiens	232-236
24360935-0	2014	Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase.	pranlukast	0-10	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	72-100
24360935-5	2014	Of the three drugs acting as CysLT1 receptor antagonists (montelukast, pranlukast and zafirlukast) tested, pranlukast was the most promising drug that inhibited MDCK cyst growth and formation without affecting cell viability.	pranlukast	107-117	cysteinyl leukotriene receptor 1	Homo sapiens	29-35
24229499-0	2014	Protective effect of pranlukast on Abeta1-42-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1.	pranlukast	21-31	cysteinyl leukotriene receptor 1	Mus musculus	106-138
24229499-4	2014	In the present study, we analysed the effects of pranlukast, a selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, on the impairment of learning and memory formation induced by Abeta and the probable underlying electrophysiological and molecular mechanisms.	pranlukast	49-59	cysteinyl leukotriene receptor 1	Mus musculus	73-105
24229499-4	2014	In the present study, we analysed the effects of pranlukast, a selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, on the impairment of learning and memory formation induced by Abeta and the probable underlying electrophysiological and molecular mechanisms.	pranlukast	49-59	cysteinyl leukotriene receptor 1	Mus musculus	107-114
24229499-8	2014	Furthermore, pranlukast reversed Abeta1-42-induced CysLT1R upregulation, and markedly suppressed the Abeta1-42-triggered NF-kappaB pathway, caspase-3 activation and Bcl-2 downregulation in the hippocampus and prefrontal cortex in mice.	pranlukast	13-23	cysteinyl leukotriene receptor 1	Mus musculus	51-58
24229499-8	2014	Furthermore, pranlukast reversed Abeta1-42-induced CysLT1R upregulation, and markedly suppressed the Abeta1-42-triggered NF-kappaB pathway, caspase-3 activation and Bcl-2 downregulation in the hippocampus and prefrontal cortex in mice.	pranlukast	13-23	caspase 3	Mus musculus	140-149
24229499-8	2014	Furthermore, pranlukast reversed Abeta1-42-induced CysLT1R upregulation, and markedly suppressed the Abeta1-42-triggered NF-kappaB pathway, caspase-3 activation and Bcl-2 downregulation in the hippocampus and prefrontal cortex in mice.	pranlukast	13-23	B cell leukemia/lymphoma 2	Mus musculus	165-170
24360935-8	2014	Interestingly, pranlukast enhanced AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta) with consequent activation of acetyl-CoA carboxylase (ACC) and suppression of mammalian target of rapamycin (mTOR) pathway.	pranlukast	15-25	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	35-39
24971371-3	2014	Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast.	pranlukast	262-272	cysteinyl leukotriene receptor 1	Homo sapiens	196-212
24360935-8	2014	Interestingly, pranlukast enhanced AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta) with consequent activation of acetyl-CoA carboxylase (ACC) and suppression of mammalian target of rapamycin (mTOR) pathway.	pranlukast	15-25	calcium/calmodulin dependent protein kinase kinase 2	Homo sapiens	112-121
24360935-8	2014	Interestingly, pranlukast enhanced AMPK activation via calcium/calmodulin-dependent protein kinase kinase beta (CaMKKbeta) with consequent activation of acetyl-CoA carboxylase (ACC) and suppression of mammalian target of rapamycin (mTOR) pathway.	pranlukast	15-25	mechanistic target of rapamycin kinase	Homo sapiens	201-230
24269024-5	2014	The CysLT1R antagonist pranlukast not only reversed Abeta1-42-induced upregulation of CysLT1R, but also suppressed Abeta1-42-triggered neurotoxicity evidenced by enhanced nuclear factor-kappa B p65, activated caspase-3, decreased B-cell lymphoma-2 and cell viability and impaired memory.	pranlukast	23-33	cysteinyl leukotriene receptor 1	Mus musculus	4-11
24269024-5	2014	The CysLT1R antagonist pranlukast not only reversed Abeta1-42-induced upregulation of CysLT1R, but also suppressed Abeta1-42-triggered neurotoxicity evidenced by enhanced nuclear factor-kappa B p65, activated caspase-3, decreased B-cell lymphoma-2 and cell viability and impaired memory.	pranlukast	23-33	cysteinyl leukotriene receptor 1	Mus musculus	86-93
24269024-5	2014	The CysLT1R antagonist pranlukast not only reversed Abeta1-42-induced upregulation of CysLT1R, but also suppressed Abeta1-42-triggered neurotoxicity evidenced by enhanced nuclear factor-kappa B p65, activated caspase-3, decreased B-cell lymphoma-2 and cell viability and impaired memory.	pranlukast	23-33	caspase 3	Mus musculus	209-218
24971371-3	2014	Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast.	pranlukast	262-272	cysteinyl leukotriene receptor 1	Homo sapiens	214-221
23859232-7	2013	Most common among them are classical CysLT1 receptor antagonists such as montelukast, zafirlukast, pranlukast, pobilukast, iralukast, cinalukast and MK571.	pranlukast	99-109	cysteinyl leukotriene receptor 1	Mus musculus	37-43
23615224-1	2013	An attempt was made to clarify the additive suppressive effects of pranlukast, a cysteinyl leukotriene-receptor (LTR) antagonist, in combination with chlorpheniramine, an antihistamine, on the up-regulation of histamine H1-receptor (H1R) mRNA in toluene 2,4-diisocyanate (TDI)-sensitized rats.	pranlukast	67-77	histamine receptor H 1	Rattus norvegicus	210-231
22571867-8	2013	In patients with increased serum MMP-9 before pranlukast therapy (baseline), comparison of paired serum levels showed a significant decrease after pranlukast therapy.	pranlukast	46-56	matrix metallopeptidase 9	Homo sapiens	33-38
22571867-8	2013	In patients with increased serum MMP-9 before pranlukast therapy (baseline), comparison of paired serum levels showed a significant decrease after pranlukast therapy.	pranlukast	147-157	matrix metallopeptidase 9	Homo sapiens	33-38
22571867-10	2013	Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1beta, IL-6, and TNFalpha), and four showed decreased sTNFR1, after pranlukast treatment, and only a responder had markedly decreased frequency of CD8+ T cells in CSF.	pranlukast	67-77	interleukin 1 beta	Homo sapiens	124-132
22571867-10	2013	Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1beta, IL-6, and TNFalpha), and four showed decreased sTNFR1, after pranlukast treatment, and only a responder had markedly decreased frequency of CD8+ T cells in CSF.	pranlukast	67-77	interleukin 6	Homo sapiens	134-138
22571867-10	2013	Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1beta, IL-6, and TNFalpha), and four showed decreased sTNFR1, after pranlukast treatment, and only a responder had markedly decreased frequency of CD8+ T cells in CSF.	pranlukast	67-77	tumor necrosis factor	Homo sapiens	144-152
22571867-11	2013	Pranlukast reduces seizure frequencies probably by pleiotropic effects including normalization of MMP-9 in sera, reduced leakage of pro-inflammatory cytokines into CNS, and inhibition of extravasation of leucocytes from brain capillaries.	pranlukast	0-10	matrix metallopeptidase 9	Homo sapiens	98-103
23684692-1	2013	Because of their favourable safety profile and beneficial anti-inflammatory properties, the CysLT1 receptor antagonists (LTRA), montelukast, zafirlukast and pranlukast are approved for the treatment of asthma and are frequently prescribed as add-on therapeutics to reduce the amount of inhaled glucocorticoids and beta2-agonists.	pranlukast	157-167	cysteinyl leukotriene receptor 1	Homo sapiens	92-98
23684692-1	2013	Because of their favourable safety profile and beneficial anti-inflammatory properties, the CysLT1 receptor antagonists (LTRA), montelukast, zafirlukast and pranlukast are approved for the treatment of asthma and are frequently prescribed as add-on therapeutics to reduce the amount of inhaled glucocorticoids and beta2-agonists.	pranlukast	157-167	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	314-319
22982445-5	2013	Pretreatment with pranlukast (1.5 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.	pranlukast	18-28	cysteinyl leukotriene receptor 1	Mus musculus	74-83
23615224-1	2013	An attempt was made to clarify the additive suppressive effects of pranlukast, a cysteinyl leukotriene-receptor (LTR) antagonist, in combination with chlorpheniramine, an antihistamine, on the up-regulation of histamine H1-receptor (H1R) mRNA in toluene 2,4-diisocyanate (TDI)-sensitized rats.	pranlukast	67-77	histamine receptor H 1	Rattus norvegicus	233-236
23615224-2	2013	Although pre-treatment with pranlukast partially, but significantly, suppressed TDI-induced up-regulation of H1R mRNA and nasal symptoms, pre-treatment with the combination of pranlukast and chlorpheniramine significantly suppressed them in a manner greater than either drug alone.	pranlukast	28-38	histamine receptor H 1	Rattus norvegicus	109-112